December 2018 - Volume 43 - Issue 12 - Contributor Index

Alphabetical Search
A
F
G
H
I
J
L
N
O
P
Q
S
T
U
V
Y
Z
Author:
Author:
Byland, Emily

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Israeli staff nurse knowledge and perception of the nurse practitioner role

Dickman, Chaya; Miller, Tamar; Muchow, Lori; More

The Nurse Practitioner. 43(12):42-48, December 2018.

This study assessed Israeli nurses' knowledge of the emerging role of master's-prepared NPs. Based on an integrated review of the literature, a study-specific survey was developed. Analyses of the 146 responses revealed that exposure to NPs was limited. Knowledge specific to the role was lacking, yet the assessment capabilities and overall perception of NPs were positive. Data demonstrate a willingness to include NPs in the care model and an awareness that doing so would positively contribute to the overall health of patients.

Author:
Dunlap, Jordan

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Adverse childhood experiences and implementing trauma-informed primary care

Esden, Jana L.

The Nurse Practitioner. 43(12):10-21, December 2018.

Adverse childhood experiences (ACEs) include exposures such as abuse and household dysfunction. These exposures are associated with long-term sequelae and unfavorable health outcomes in adulthood. NPs working in primary care can help to reduce the impact of ACEs in adulthood by identifying individuals with these experiences and implementing trauma-informed care strategies.

Israeli staff nurse knowledge and perception of the nurse practitioner role

Dickman, Chaya; Miller, Tamar; Muchow, Lori; More

The Nurse Practitioner. 43(12):42-48, December 2018.

This study assessed Israeli nurses' knowledge of the emerging role of master's-prepared NPs. Based on an integrated review of the literature, a study-specific survey was developed. Analyses of the 146 responses revealed that exposure to NPs was limited. Knowledge specific to the role was lacking, yet the assessment capabilities and overall perception of NPs were positive. Data demonstrate a willingness to include NPs in the care model and an awareness that doing so would positively contribute to the overall health of patients.

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Israeli staff nurse knowledge and perception of the nurse practitioner role

Dickman, Chaya; Miller, Tamar; Muchow, Lori; More

The Nurse Practitioner. 43(12):42-48, December 2018.

This study assessed Israeli nurses' knowledge of the emerging role of master's-prepared NPs. Based on an integrated review of the literature, a study-specific survey was developed. Analyses of the 146 responses revealed that exposure to NPs was limited. Knowledge specific to the role was lacking, yet the assessment capabilities and overall perception of NPs were positive. Data demonstrate a willingness to include NPs in the care model and an awareness that doing so would positively contribute to the overall health of patients.

Prediabetes: Early identification and management

Rariden, Christina

The Nurse Practitioner. 43(12):35-40, December 2018.

Prediabetes continues to be a national and worldwide health concern, affecting 84 million adults in the US. Early identification and intervention have been successful in delaying and/or preventing the progression to type 2 diabetes mellitus (T2DM). Nonpharmacologic treatment of prediabetes is paramount, although pharmacologic treatment is appropriate in high-risk patients. In an attempt to curb the increasing prevalence of T2DM, recognizing the importance of identifying and managing prediabetes should remain in the national healthcare forefront.

Israeli staff nurse knowledge and perception of the nurse practitioner role

Dickman, Chaya; Miller, Tamar; Muchow, Lori; More

The Nurse Practitioner. 43(12):42-48, December 2018.

This study assessed Israeli nurses' knowledge of the emerging role of master's-prepared NPs. Based on an integrated review of the literature, a study-specific survey was developed. Analyses of the 146 responses revealed that exposure to NPs was limited. Knowledge specific to the role was lacking, yet the assessment capabilities and overall perception of NPs were positive. Data demonstrate a willingness to include NPs in the care model and an awareness that doing so would positively contribute to the overall health of patients.

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Author:
Xiong, Linda

Drug updates and approvals: 2018 in review

Mospan, Cortney; Mospan, Geoffrey; Byland, Emily; More

The Nurse Practitioner. 43(12):23-32, December 2018.

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).